The Right Treatment for Alzheimer’s Disease

A remarkable study by Dean Ornish, MD, and Rudolph Tanzi, PhD, published in Alzheimer’s Research & Therapy (2024), is challenging long-held assumptions about Alzheimer’s disease and reinforcing a message I explore in depth in my upcoming book, Brain Defenders: the brain is not a passive victim of degeneration, but a dynamic organ that responds continuously to the signals we provide through our daily choices.

In this randomized controlled trial, individuals with mild cognitive impairment or early Alzheimer’s disease were assigned either to usual care or to an intensive lifestyle intervention targeting multiple domains including nutrition, physical activity, stress management, sleep, and social engagement. This wasn’t a modest recommendation to “eat better and exercise.” It was a structured, comprehensive program designed to influence the very biology underlying brain function. And the results were nothing short of remarkable.

After just 20 weeks, participants in the intervention group demonstrated statistically significant improvements in cognition and daily function.

Importantly, approximately 70% of participants in the intervention group either improved or stabilized, whereas the control group followed the expected trajectory of decline.

Let’s pause there for a moment and take in what I just revealed.

We are not talking about slowing the rate of decline. We are talking about measurable improvement in individuals already diagnosed with early Alzheimer’s disease.

Even more compelling, these clinical outcomes were supported by objective biological changes. Participants in the lifestyle group showed improvements in metabolic markers, including reductions in insulin resistance and better glycemic control which are factors we know are deeply connected to brain health. There were also reductions in inflammatory markers and favorable shifts in Alzheimer’s-related biomarkers such as the Aβ42/40 ratio. And critically, there was a clear dose-response relationship meaning the more closely participants adhered to the intervention, the greater the benefit.

This is exactly what we would predict if Alzheimer’s disease is fundamentally driven by disturbances in metabolism and immune regulation. In Brain Defenders, I focus extensively on the role of microglia, the brain’s resident immune cells, as central players in this process.

Microglia are exquisitely sensitive to signals related to blood sugar, inflammation, oxidative stress, and even social connection.

When those signals are unfavorable, microglia can become chronically activated, leading to synaptic destruction and cognitive decline. But when we improve those signals, we can shift microglial behavior toward protection and repair.

Now contrast these findings with the current pharmaceutical paradigm.

A newly published 2026 Cochrane review in the Cochrane Database of Systematic Reviews, analyzing over 20,000 patients across 17 randomized trials of anti-amyloid monoclonal antibodies, reached a sobering conclusion. These FDA approved drugs, designed to remove amyloid from the brain, produce “little to no difference” in cognitive outcomes, with effects deemed “trivial,” while increasing the risk of brain swelling and microbleeds (ARIA) .

So we are left with a striking paradox.

We can successfully remove amyloid from the brain, yet fail to meaningfully improve cognition, and in doing so, expose patients to measurable risk. Meanwhile, a comprehensive lifestyle intervention, safe, accessible, and cost-effective, demonstrates not just stabilization, but actual improvement.

This juxtaposition demands that we reconsider our framework for understanding Alzheimer’s disease. If removing amyloid does not translate into meaningful clinical benefit, then perhaps amyloid is not the primary driver of the disease, but rather a downstream manifestation of deeper biological dysfunction.

That dysfunction, as I emphasize in Brain Defenders, involves the intersection of metabolism, inflammation, and immune signaling. It is a dynamic process, one that can be influenced, positively or negatively, by the choices we make every day.

What this study ultimately tells us is profoundly important. Alzheimer’s disease, particularly in its early stages, may not be a fixed, irreversible condition. It may be, at least in part, modifiable. And the tools to influence that trajectory are not limited to pharmaceuticals. They include the very elements of daily life, what we eat, how we move, how we sleep, how we manage stress, and how we connect with others.

This is an empowering message because it shifts the conversation away from inevitability and toward possibility. It reminds us that the brain has intrinsic defense systems, systems that can be supported, nurtured, and even reprogrammed. When we change the signals, we change the outcome.